Colo-205 as a translational imaging model for colorectal cancer

Contact the preclinical oncology scientific team to learn more. 

As mentioned in our HT-29 Model Spotlight last October, colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States for men and women combined. The death rate from CRC has been declining over the past several decades and there are now more than one million CRC survivors in the United States. However, there were still 95,000 new cases diagnosed in 2016.

Of these new CRC cases, about 10 percent of patients are characterized by a mutation in the B-Raf protooncogene serine/threonine kinase (BRAF) gene resulting in a valine-to-glutamate change at the residue 600 (V600E).1 BRAF is a known important player within the Mitogen-activated protein kinase (MAPK) pathway and known to have profound effects on cell growth, proliferation, and cell differentiation.2 Clinically, BRAF inhibitors have been shown to have remarkable ability to inhibit tumor metabolism as measured by 18F-deoxyglucose positron emission tomography (¹⁸FDG-PET)^.3

Table 1: Colorectal Cancer Models

At Labcorp, we have a number of CRC models (see Table 1) and Colo-205 represents one of our most highly utilized lines with the BRAF mutation. We have also applied preclinical ¹⁸FDG-PET to test translational applications. Figure 1 illustrates efficacy of a BRAF inhibitor against subcutaneous Colo-205 in nude mice. Colo-205 has also shown to be ¹⁸FDG-PET avid and tumor metabolism modulation can be observed with BRAF treatment (Figures 2 and 3).

Fig. 2: FDG-PET SUV Mean Following Treatment with a BRAF Inhibitor

Fig. 3: Images of FDG-PET Colo-205 Subcutaneous Tumor

References

²Matallanas D, Birtwistle M, Romano D, et al. Raf family kinases: old dogs have learned new tricks. Genes Cancer. 2011;2(3):232–260.